<DOC>
	<DOCNO>NCT00448461</DOCNO>
	<brief_summary>PROTOCOL SYNOPSIS Title : Comparison bivalirudin unfractioned heparin ( UFH ) + protamine elective percutaneous coronary intervention ( PCI ) Design : Prospective , randomize , control trial Hypothesis : Bivalirudin superior UFH + protamine improvement outcomes patient undergo elective PCI Key Inclusion Criteria : Patients older 18 year age undergo PCI Clopidogrel load &gt; 6 hrs prior PCI accord PCI guideline Informed , write consent Key Exclusion Criteria : ST-elevation myocardial infarction within prior 48 hour Active bleeding , bleed diathesis , recent surgery Severe renal failure Chronic coronary artery occlusion treat Primary endpoint : Inhospital major bleed Secondary endpoint : 1 . Composite rate death , myocardial infarction ( MI ) target vessel revascularization ( TVR ) inhospital , 6 month 2 . Composite rate inhospital death , MI TVR major bleed 3 . Major minor bleeding 4 . Total vascular complication 5 . Post-procedure renal failure Randomization : Bivalirudin versus unfractioned heparin follow protamine end PCI procedure Sample size : Assumed incidence inhospital major bleed 6 % UFH + protamine 2 % bivalirudin group ; power 80 % level 0.05 group 425 patient need . An interim analysis perform enrolment 425 ( 50 % ) patient . Follow-up : Inhospital , 6-month clinical follow-up ( out-patient clinic phone )</brief_summary>
	<brief_title>Antithrombotic Regimens Outcome</brief_title>
	<detailed_description>Bivalirudin , direct thrombin inhibitor , recently introduce alternative UFH give several important biologic pharmacokinetic advantages.1,2 In contrast UFH , act independently antithrombin inhibits free clotbound thrombin ; neutralize circulating inhibitor ; bind plasma protein cause thrombocytopenia.1,2 In Bivalirudin Angioplasty Study , bivalirudin associate 45 % reduction relative risk composite death , myocardial infarction , revascularization hemorrhage compare UFH among patient unstable angina undergo percutaneous coronary angioplasty.3 Recently , another randomized trial patient intermediate risk undergo coronary stenting vary pre-treatment interval different dos thienopyridines , use bivalirudin estimate result 38 % reduction relative risk death , myocardial infarction , urgent repeat revascularization in-hospital major bleed 30 day compare UFH.4 In addition , bivalirudin associate similar rate ischemic event less major bleed estimate cost-effective abciximab administer adjunct UFH.4,5 However , previous study include patient treat plain balloon angioplasty stenting inadequate pretreatment thienopyridines ( ticlopidine clopidogrel ) . Recent guideline recommend patient undergoing PCI must receive load dose 300 - 600 mg clopidogrel.6 Clopidogrel thienopyridine act irreversibly inhibiting platelet adenosine 5'- diphosphate ( ADP ) receptor . Compared ticlopidine , advantage favourable side effect profile 7 , 8 rapid onset action.9 Pre-treatment clopidogrel associate well outcome among patient undergo PCI.10-12 After load dose 600 mg , maximum inhibition aggregation clopidogrel achieve within two hours.13 The Intracoronary Stenting Antithrombotic Regimen-Rapid Early Action Coronary Treatment ( ISAR-REACT ) trial show pre-treatment 600 mg clopidogrel least 2 hour intervention , additional use abicximab UFH associate clinically measurable benefit among low-to-intermediate risk patient underwent PCI.14 On hand , patient receive abciximab high rate thrombocytopenia frequently require blood transfusion . Thus , antithrombotic strategy consist load dose 600 mg clopidogrel addition UFH aspirin safe effective way improve patient ' outcome reduce cost PCI . There data use protamine neutralization circulate heparin successful stent implantation.15-18 However , previous study show excess ischemic complication stent implantation subsequent protamine administration , strong potential bleeding complication limitation . Based above-mentioned data say antithrombotic regimen base either bivalirudin UFH intraprocedurally follow protamine neutralization , effective strategy reduce ischemic hemorrhagic complication patient coronary artery disease undergo PCI . At present , know whether bivalirudin superior UFH patient optimally pre-treated load dose clopidogrel . We design study ass whether bivalirudin superior unfractioned heparin + protamine patient undergoing PCI . All patient older 18 year age , require coronary angiography suspect establish coronary artery disease , without ST-segment change , receive load dose 600 mg clopidogrel least 2 hour prior procedure . Eligible patient meet exclusion criterion angiography reveals revascularization require target lesion ( ) ( ) amenable PCI , randomize receive bolus 140 U/kg heparin bivalirudin administer intravenous bolus 0.75 mg/kg prior start intervention , follow infusion 1.75 mg/kg per hour duration procedure . All patient receive aspirin indefinitely clopidogrel least 1 month PTCA implantation bare metal stent least 6 month implantation drug-eluting stent ; clopidogrel treatment 6 month encouraged.19 The primary end point study in-hospital major bleeding . The study design show whether bivalirudin superior UFH + protamine respect primary end point .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Patients old age 18 undergo PCI 2 . Pretreatment least 6 hour PCI clopidogrel accord PCI guideline . 3 . Informed , write consent patient her/his legallyauthorized representative participation study . 1 . Recent STelevation myocardial infarction within last 48 hour . 2 . Chronic coronary artery occlusion treat 3 . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le one year may result protocol noncompliance . 4 . Active bleeding , bleed diathesis , recent surgery ( &lt; 15 day ) 5 . History gastrointestinal genitourinary bleeding within last 6 week 6 . Treatment UFH within 6 hour lowmolecular weight heparin within 8 hour randomization . 7 . Treatment bivalirudin within 24 hour beforerandomization . 8 . Severe uncontrolled hypertension &gt; 180/110 mmHg unresponsive therapy 9 . Relevant hematologic deviation : hemoglobin &lt; 100 g/L OR platelet count &lt; 100 x 109 /L . 10 . Glomerular filtration rate ( GFR ) &lt; 30 ml/min serum creatinine &gt; 30 mg/L dependence renal dialysis . 11 . Known allergy study medication : aspirin , clopidogrel , UFH , bivalirudin ; stainless steel ; true anaphylaxis prior exposure contrast medium . 12 . Known heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>